Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR

Alimentary Pharmacology and Therapeutics - Tập 30 Số 7 - Trang 733-740 - 2009
Christos Toumpanakis1, J. Garland1, Laura Marelli1, Rajaventhan Srirajaskanthan1, Jade Xiao Jue Soh1, Philippa Davies1, John Buscombe1, Martyn Caplin1
1Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK

Tóm tắt

SummaryBackground  Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow‐up are lacking.Aim  To present long‐terms results with octreotide LAR, assessing duration of clinical and objective response and treatment tolerance, in a large, homogeneous cohort of patients with malignant carcinoid syndrome.Methods  A total of 108 patients with metastatic midgut neuroendocrine tumours were included in this 8‐year study. Clinical evaluation was based on a symptom score. Radiological assessment was based on RECIST (Response Evaluation Criteria In Solid Tumours) criteria.Results  Of the 108 patients, 24% had a sustained symptomatic response. In the remaining patients, loss of symptomatic response with the initial dose was noted within 3‐60 months. In 17% of them, symptoms were controlled by just an increase of octreotide LAR dose, whilst the other patients required additional treatment. Overall, in 45.3% of patients, symptoms were well controlled during the study period with only octreotide LAR, and no additional treatment was required. No significant adverse effects were noted.Conclusions  Octreotide LAR treatment provides a sustained symptomatic response in about half of the patients with malignant carcinoid syndrome and contributes to disease stabilization for a longer period than previously described.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.2007.15.4377

10.1016/S1470-2045(07)70410-2

Kvols LK, 2007, A Century of Advances in Neuroendocrine Tumour Biology and Treatment, 354

10.1023/A:1027392228418

Pless J, 2005, The history of somatostatin analogs, J Endocrinol Invest, 28, 1

10.1093/annonc/mdh216

10.1136/gut.38.3.430

10.1016/j.bpg.2005.02.012

10.1200/JCO.1999.17.2.600

10.1046/j.1365-2036.2003.01420.x

10.1007/s00428-007-0452-1

Wessels FJ, 2001, Radiofrequency ablation treatment of refractory carcinoid hepatic metastases, J Surg Res, 85, 8, 10.1006/jsre.2000.5988

10.1046/j.1365-2036.2000.00738.x

10.3109/02841869309083916

10.1016/j.cgh.2005.12.008

10.1016/j.beem.2007.01.002

10.1093/jnci/81.7.531

10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4

10.1530/eje.0.1510107

10.1159/000111034

Perry LJ, 1994, Hepatic arterial chemoembolization for metastatic neuroendocrine tumors, Surgery, 116, 1111

10.1200/JCO.2005.08.066

10.1159/000111037

10.1677/ERC-08-0017

10.1016/j.ejca.2007.07.025

10.1159/000162876

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 30 Số 7

733-740

Thông tin tác giả